The researchers in the iSenseDNA project want to develop technology that can connect changes in a biomolecule’s structure to its function during complex dynamic processes in real time. Technologies currently exist to help study how a certain molecule functions during a biological process, and there are technologies for studying the structure of molecules in detail. However, none has managed to connect structure to function on a large scale. This makes it difficult to predict which structural changes are needed to improve a drug, for example.
Of vital importance for the project will be the fast non-invasive optical readout of biomolecular samples. At DESY, researchers explore how this can be achieved leveraging photonic ultrafast light sources. “Such light sources can in principle be integrated on photonic chips and may lead to new compact and low-cost precision sensors”, says Tobias Herr who is leading the team at DESY.
In the project, the researchers will combine computational and biotechnological methods as tools for advanced optical analysis of biomolecules “in action”. Together they want to develop a so-called nano-transducer, a DNA-based sensor that is sensitive to structural changes and can read these in real-time.
“This multidisciplinary project establishes a collaboration between different fields and technologies that has the potential to extract otherwise well-hidden information about complex processes, which will eventually contribute to advances in medical diagnostics and treatment,” says Lynn Kamerlin (Uppsala University), one of the coordinators of the project.
The researchers within iSenseDNA come from universities (Uppsala, Umeå, and Padova universities), research centres (CNR, BIO, DESY, ESRF), and a company (OrganoTherapeutics, OT) across Europe (Sweden, Italy, Spain, Germany, Luxembourg, France). The project has a total budget of approximately three million euros and is financed by the European Innovation Council within the framework of the EIC pathfinder Open Call.
Biotech & Pharma, Forschung & Hochschulen
Osteolabs technology can detect bone metastases early
Crown Bioscience to Acquire Indivumed’s Service Business
Biotech & Pharma, LSN